Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma

BMC Clinical Pathology

Volumn 14, Issue 1, 2014, Pages

  Von Klot, Christoph A ^a   Kramer, Mario W ^a   Peters, Inga ^a   Hennenlotter, Joerg ^b   Abbas, Mahmoud ^a   Scherer, Ralph ^a   Herrmann, Thomas R W ^a   Stenzl, Arnulf ^b   Kuczyk, Markus A ^a   Serth, Juergen ^a   Merseburger, Axel S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Biomarker; Galectin; Prognosis; Renal cell carcinoma

Indexed keywords

GALECTIN 1; GALECTIN 3;

ADULT; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VISCERAL METASTASIS;

EID: 84901189783     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-14-15     Document Type: Article

References (38)

1. Epidemiology of renal cell carcinoma. Lindblad P, Scand J Surg 2004 93 2 88 96 15285559 (Pubitemid 38937647)
2. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN, Cancer Epidemiol Biomarkers Prev 2010 19 6 1460 1467 10.1158/1055-9965.EPI-09-1310 20501756
3. Risk factors for adult renal cell carcinoma. Dhote R, Thiounn N, Debré B, Vidal-Trecan G, Urol Clin North Am 2004 31 2 237 247 10.1016/j.ucl.2004.01.004 15123404 (Pubitemid 38581222)
4. Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989. Katz DL, Zheng T, Holford TR, Flannery J, Int J Cancer 1994 58 1 57 63 10.1002/ijc.2910580111 8014016 (Pubitemid 24213970)
5. Prognostic factors of renal cell carcinoma. Mejean A, Oudard S, Thiounn N, J Urol 2003 169 3 821 827 10.1097/01.ju.0000051378.14270.2a 12576793 (Pubitemid 36188101)
6. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Kwak C, Park YH, Jeong CW, Lee SE, Ku JH, Urol Int 2007 79 2 145 151 10.1159/000106329 17851285 (Pubitemid 47402741)
7. Galectins structure and function-a synopsis. Leffler H, Results Probl Cell Differ 2001 33 57 83 10.1007/978-3-540-46410-5-4 11190679
8. Galectins as modulators of cell adhesion. Hughes RC, Biochimie 2001 83 7 667 676 10.1016/S0300-9084(01)01289-5 11522396 (Pubitemid 32821230)
9. Hughes RC:Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. Kasper M, J Pathol 1996 179 3 309 316 10.1002/(SICI)1096-9896(199607)179:3<309::AID- PATH572>3.0.CO;2-D 8774488 (Pubitemid 26266411)
10. Galectins: a family of animal beta-galactoside-binding lectins. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Cell 1994 76 4 597 598 10.1016/0092-8674(94) 90498-7 8124704 (Pubitemid 24070645)
11. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Prostate 2008 68 1 72 77 10.1002/pros.20688 18008332
12. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS, Oncol Rep 2008 20 6 1403 1408 19020721
13. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C, Kiss R, Oral Oncol 2008 44 1 86 93 10.1016/j.oraloncology.2006.12.014 17350328 (Pubitemid 350251284)
14. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, André S, Gabius H-J, Laurent G, Thyroid 2008 18 7 705 712 10.1089/thy.2007.0361 18630998 (Pubitemid 352009927)
15. Potential tumor markers of renal cell carcinoma: Alpha-Enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Kaneko N, Gotoh A, Okamura N, Matsuo E-I, Terao S, Watanabe M, Yamada Y, Hamami G, Nakamura T, Ikekita M, Okumura K, Nishimura O, Int J Urol 2012 20 5 530 535 23113677
16. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Sobin LH, Compton CC, Cancer 2010 116 22 5336 5339 10.1002/cncr.25537 20665503
17. Prognostic significance of morphologic parameters in renal cell carcinoma. Fuhrman SA, Lasky LC, Limas C, Am J Surg Pathol 1982 6 7 655 663 10.1097/00000478-198210000-00007 7180965 (Pubitemid 13234762)
18. Pathology, biology, and clinical staging of renal cell carcinoma. Stenzl A, deKernion JB, Semin Oncol 1989 16 1 Suppl 1 3 11 (Pubitemid 19086385)
19. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
20. R Core Team, R: A Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing 2013 [ http://www.R-project.org/ ]
21. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A, Mol Med 2010 16 3-4 102 115 20200618
22. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Buttery R, Monaghan H, Salter DM, Sethi T, Histopathology 2004 44 4 339 344 10.1111/j.1365-2559.2004.01815.x 15049899 (Pubitemid 38491300)
23. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, Hanisch FG, Mönig SP, Schröder W, Flucke U, Thiele J, Hölscher AH, Dienes HP, Tumour Biol 2000 21 5 258 266 10.1159/000030131 10940822 (Pubitemid 30666030)
24. Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S, Bull Cancer 2010 97 2 1 E8 20080461
25. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS, Am J Pathol 2001 158 5 1639 1651 10.1016/S0002-9440(10)64120-X 11337362 (Pubitemid 32422929)
26. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. François C, van Velthoven R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, Salmon I, Gabius HJ, Danguy A, Decaestecker C, Kiss R, Am J Clin Pathol 1999 112 2 194 203 10439799 (Pubitemid 30212535)
27. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T, Cell Biol Int 2007 31 7 655 662 10.1016/j.cellbi.2006.11.036 17222570 (Pubitemid 46765120)
28. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. Merseburger AS, Kramer MW, Hennenlotter J, Serth J, Kruck S, Gracia A, Stenzl A, Kuczyk MA, World J Urol 2008 26 6 637 642 10.1007/s00345-008-0294-8 18594826
29. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H, Kanayama H-O, J Med Invest 2010 57 1-2 152 157 20299755
30. Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Zhang D, Chen Z-G, Liu S-H, Dong Z-Q, Dalin M, Bao S-S, Hu Y-W, Wei F-C, Acta Pharmacol Sin 2013 34 1 176 184 10.1038/aps.2012.150 23103626
31. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung M-C, Bresalier RS, Cancer Res 2009 69 4 1343 1349 10.1158/0008-5472.CAN-08-4153 19190323
32. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Fukumori T, Takenaka Y, Yoshii T, Kim H-RC, Hogan V, Inohara H, Kagawa S, Raz A, Cancer Res 2003 63 23 8302 8311 14678989 (Pubitemid 37549482)
33. Galectin-3 regulates T-cell functions. Hsu DK, Chen HY, Liu FT, Immunol Rev 2009 230 1 114 127 10.1111/j.1600-065X.2009.00798.x 19594632
34. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF, Cancer Res 2008 68 17 7228 7236 10.1158/0008-5472.CAN-08-1245 18757439
35. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. Zuñiga E, Rabinovich GA, Iglesias MM, Gruppi A, J Leukoc Biol 2001 70 1 73 79 11435488 (Pubitemid 32613665)
36. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Fuertes MB, Molinero LL, Toscano MA, Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW, Rabinovich GA, Mol Cell Biochem 2004 267 1-2 177 185 15663199 (Pubitemid 39562398)
37. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Masui O, White NMA, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, Pace K, Bjarnason GA, Siu KWM, Yousef GM, Mol Cell Proteomics 2013 12 1 132 144 10.1074/mcp.M112.020701 23082029
38. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. Straube T, Elli AF, Greb C, Hegele A, Elsässer H-P, Delacour D, Jacob R, J Exp Clin Cancer Res 2011 30 89 10.1186/1756-9966-30-89 21958686